Nicofi Targets Selling E-Cigarette Users And Smokers On A Substitute
This article was originally published in The Tan Sheet
Executive Summary
Ross Myles Health is not making a smoking cessation or NRT claim for Nicofi sublingual tablets made with steam-extracted pure nicotine, keeping the product free of drug regulation by FDA. While Nicofi also is outside the agency’s current tobacco product authority, the firm is prepared for FDA oversight.
You may also be interested in...
E-Cigarettes Spark Evolution Of FDA’s Nicotine-Containing Medical Product Regulation
FDA’s tobacco, drug and medical device centers are discussing “some sort of jurisdictional policy” to “determine how to evolve the regulation of therapeutic nicotine products,” including OTC drugs, says tobacco program head Mitch Zeller.
Smoking Cessation Label Changes Could Lay Groundwork For Indications
FDA drops its requirement for labeling provisions for NRTs on duration of use and concomitant use of tobacco or other NRTs. Meanwhile, the agency rejects citizen petition requests for additional NRT indications, but says it is open to working with sponsors on developing those indications.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”